1. Introduction
1.1. Background
Microbes have evolved over the past decades and influence human gut health, impacting the immune and central nervous system functions. The bacteria, fungi, viruses, and other gut microorganisms symbiotically relate with the host to consume the required nutrients and secret beneficial chemicals for the biochemical processes. The microbiomes consume their needed gut nutrients and secrete chemicals such as amino acids, which manage and control biochemical processes such as immune response and homeostasis [ 1 , 2 , 3 , 4 ]. It develops in one’s system from infancy and becomes a crucial part of the metabolic and immune systems. The interdependent relationship suggests a strong relationship between the gut microbiome, cognitive health, and central nervous functions.
Multiple communication pathways link the gut microbiome to the central nervous system (CNS). The gut and the brain communicate through the circulatory system, immune system, vagus nerve, neuroendocrine system, and enteric nervous system (ENS) [ 4 , 5 , 6 ]. The microbiome produces bloodstream chemicals that easily reach the brain and produce neurotransmitters and metabolites that convey bidirectional information between the gut and the brain. Communications via the immune system occur through cytokines produced in the gut and can travel to the brain through the bloodstream. Communication through the vagus nerve occurs when sensory information from the gut is transmitted to the brain through the nerve fibers, while the brain responds through gut functions. Communications through the neuroendocrine system also occur through the vagus nerve; specialized gut wall cell linings release hormones that travel through the bloodstream, ensuring communications between the two systems. The communication relationships and interdependencies allude to the possibility of gut microbiome contributing to certain neurological disorders, such as Alzheimer’s and multiple sclerosis, alongside other genetic, environmental, and lifestyle influences.
Debates have also risen over the existence of microbes in the brain. The studies hypothesize that bacteria, fungi, and viruses exist in the brain. Possibilities emerged of brain microbiomes that influence the development of neurodegenerative diseases, specifically Alzheimer’s disease (AD) and Parkinson’s disease (PD) [ 6 ]. The gut–brain axis is based on the concept of a brain microbiome. According to this theory, the CNS contains a microbiota that has a similar relationship with the human body as that of the gut microbiome [ 7 ]. Researchers have also detected disease-associated altered microbiomes related to multiple disorders spanning Alzheimer’s disease, autism spectrum disorder, attention-deficit hyperactivity disorder, Huntington’s disease, major depressive disorder, multiple sclerosis, and Parkinson’s disease [ 8 , 9 ]. Research stipulates that the microbes interact with the CNS to influence neuron signaling, neuroinflammation, and other brain health aspects. Certain studies also found no microbiomes in the brains of AD and PD patients [ 10 ]. The lack of consistent information on whether microbes exist in the brain and their relative impacts necessitates further research to bridge the knowledge gap.
The relationship between the gut microbiome and the central nervous system is integral to the future of neurological health. Past studies show that the gut microbiome regulates the immune system, metabolism, and neurotransmitter production; however, the mechanism defining how the microbiomes influence brain functions has not been sufficiently studied. Researchers have found communication pathways such as the circulatory system, immune signaling, and the vagus nerve that they believe, if disrupted, could influence the occurrence of neurological disorders. A plethora of research has been conducted in this field, but a major gap exists in how specific microbes interact with neural processes to influence cognitive health. Further research could reveal the mechanistic gut–brain interaction pathways to determine therapeutic targets when treating neurodegenerative and psychiatric disorders.
1.2. Knowledge Gap
Although recent research has shown that the gut microbiome has an influence on the CNS via the gut-brain axis, there is limited knowledge of the mechanisms and pathways involved in the process. The concept of the brain microbiome, which is believed to play a crucial part in the relationship between the gut and the brain, is also new, meaning the amount of research on the subject is limited. These research gaps should be addressed in future research. This systematic review consolidates current knowledge on the topic to highlight these gaps.
1.3. Aims and Objectives
To synthesize existing evidence on the gut–brain axis and investigate the mechanistic pathways that link the gut microbiome and the CNS.
To explore the novel concept of the brain microbiome and determine its existence and the role it plays in one’s neurological health.
To identify and analyze existing data on the interactions between the gut and brain microbiomes to determine their collective impact on neurological health factors such as neuroinflammation and neurodegeneration.
To point out existing gaps in research on the gut–brain axis, especially the mostly unexplored brain microbiome.
2. Materials and Methods
The materials and methods section delves into the procedures for finding articles for the systematic review. Systematic reviews follow Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) to select and analyze past studies. The PRISMA approach was developed to raise the findings’ transparency, clarity, value, and quality. This section covers the search strategy, inclusion/exclusion criteria, data extraction, data synthesis, quality assessment, and overview of the selected studies.
2.1. Search Strategy
This systematic review assesses current studies related to the gut–brain axis. The primary search is performed on the PubMed and Google Scholar databases following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) technique. The following MeSH terms helped to find the desired articles:
{“Gut-Brain Axis”/“Brain-Gut Axis”/Gut Microbiota”/“Gastrointestinal Microbiome”} + {“Microbiome”/“Microbial Interactions”/“Microbial Metabolites”/“Dysbiosis”/“Short-chain fatty acids”} + {“Central Nervous System”/“Neuroimmunology”/“Neuroinflammation”/“Blood-Brain Barrier”/“Neurotransmitters”} + {“Neurological disorders”/“Alzheimer Disease”/“Parkinson Disease”/Autism Spectrum Disorder”/“Mental Disorders”} +{“Pathogenesis”/“Disease Susceptibility”/“Risk Factors”/“Gene-environment Interaction”} + {“Genome-wide association study”/“Epigenomics”/“Transcriptome”/“Proteomics”/ “DNA Methylation”} + {“Systematic Review”/“Meta-analysis”/Case-control studies”/“Cohort Studies”}
The MeSH terms stem from key topics and factors discussed under the gut–brain axis, the gut microbiome, and the brain microbiome. The researcher copied and pasted the code into the PubMed and Google Scholar search bars to reveal a list of related studies. The researcher refined the results by adjusting the search bars’ publication dates, study type, and other components. The results were then exported to an Excel sheet for further analysis.
2.2. Inclusion/Exclusion Criteria
Vast research has examined gut–brain axis interactions through distinct perspectives. The inclusion and exclusion criteria guide the researcher in achieving the desired efficacy The inclusion and exclusion criteria hinge on the study type, study focus, population, publication date, language, data availability, and intervention studies. Below is an in-depth perspective of the inclusion and exclusion criteria.
On the study type, the systematic review only includes original research papers, meta-analyses, and systematic reviews. The researcher may also list longitudinal and cross-sectional studies if they are relevant. The prospective journal article topics should focus on the gut–brain axis, brain microbiome, and the gut microbiome. The study populations were human subjects or related animals, such as mice. The publication date of the articles must be between 2015 and 2025 to ensure up-to-date information. The research papers must be in English since it is widely used in scientific research around the globe and would permit peer reviews worldwide. The prospective studies must have original data from reputable sources such as healthcare facilities. Finally, the intervention studies should prioritize brain microbiome over other past topics to ascertain the reliability of the information. The researcher will exclude studies with insufficient data or not specific to the research context.
2.3. Study Selection and Quality Assessment
The researcher followed the PRISMA guidelines to select the ideal articles. Two independent reviewers will examine and screen the selected articles; disagreements will be resolved through discussion or a third-party arbitrator The articles will undergo initial screening, full-text analysis, and final analysis and selection. The initial screening focuses on the title and abstract, eliminating any paper irrelevant to the research subject. The full-text analysis examines whether the articles comprise key components such as background information, materials and methods, key findings, discussions, and conclusions. The final screening and selection hinge on the article’s contribution to the subject and determine its inclusion in the paper. The researcher used the Newcastle–Ottawa Scale (NOS) to examine the quality of observational studies.
2.4. Data Extraction
Data were extracted from the selected articles to determine their key findings and research outcomes. The main parts covered will include the following: Study characteristics: Basic information such as author details, publication name and data, and the research design recorded in a spreadsheet. This information was used to confirm whether the study met all inclusion criteria before inclusion. Gut–brain microbiome data: All relevant findings related to the gut–brain axis and microbiomes were extracted and recorded. This information formulated the discussion topics of the systematic review. Study limitations: All recorded or observed weaknesses were recorded. This information paints a clearer picture of the current state of research on subjects such as the brain microbiome and highlights what needs to be covered in future research. Research outcomes: The main conclusions of each article were noted and summarized before being transferred to the systematic review’s discussion section.
2.5. Data Synthesis
All data from this systematic review were recorded and analyzed qualitatively and quantitatively in Microsoft Excel. This approach allowed us to map the relationships between the gut and brain microbiomes and their influence on neurological health. Correlational analyses revealed the underlying trends and potential research gaps.
2.6. Quality Assessment
Each selected article was subjected to quality assessment to gauge the impact of its contents on this systematic review. In addition to using the inclusion/exclusion criteria and data extraction processes, documented techniques such as the Newcastle–Ottawa Scale (NOS) and the AMSTAR-2 were used to analyze observational studies and meta-analyses. The quality of a given article was estimated based on the research procedure, particularly the participant selection procedures, the type of data collected, and the comparison of the research outcomes to their aims and objectives.
3. Results
Overview of Selected Studies and PRISMA Diagram
The literature search on the Google Scholar and Pubmed databases yielded 2716 articles. The articles were screened to eliminate the duplicates, resulting in 2237. The titles and abstracts of the remaining articles were then screened to determine conformity to the preferred key terms, gut microbiome and gut–brain axis, leaving n = 298 articles. The remaining articles were further screened to remove those lacking data and full texts; in the process, 216 articles were eliminated, leaving 82 journal articles to proceed to the next stage of the research, as shown in the PRISMA diagram ( Figure 1 ).
4. Key Findings
The results offer significant insights into the relationship between the gut microbiome and brain health. The findings reveal diverse themes that could offer insights into the research and directions for proper and effective interventions. The preliminary analysis revealed that future research could exploit the relationship between the gut microbiome and brain health to address chronic conditions such as PD and AD. The key themes emerging in the study comprise the association between gut diseases and neurogenerative diseases, gut microbiota and cognitive health, gut microbiota and mental health disorders, gut microbiota and autoimmune diseases, and gut microbiota and cancer risk. Below is an in-depth perspective of the themes.
4.1. The Neurological Relevance of the Gut Microbiota
One of the major themes is the neurological relevance of the gut microbiota. The gut microbiome produces neurotransmitters such as serotonin and dopamine that regulate emotional responses, mood, and levels of cognition [ 8 , 9 , 10 , 11 , 12 ]. The neurotransmitters come with neuroactive properties, and therefore, any imbalance in the gut microbiota affects brain function and may cause symptoms such as anxiety, cognitive impairment, and depression [ 13 , 14 ]. The gut–brain axis facilitates the interaction and ensures bidirectional communications between the gut and the neurological system. The above studies prove that the gut microbiome can influence a person’s mental health. The revelation of the link between anxiety, depression, stress disorders, and gut health paves the way for possibilities to exploit future interactions to understand the relationship between the variables. The above themes reveal how microbiome-based properties could help develop therapeutic interventions to address neurological and psychiatric disorders by influencing the gut microbial composition.
4.2. Gut Imbalances and Neurological Health
The study also reveals how gut imbalances, such as microbial dysbiosis, can manifest in mental health issues like anxiety in patients; this goes to show the importance of the gut microbiome [ 15 , 16 , 17 ]. The types and number of microbiomes in the body may cause disease if not properly managed. The studies reveal that certain dietary items, for instance, proteins or sulfur, can imbalance the gut microbiome and predispose the individual to neurological diseases. The studies also revealed that stress contributes to gut imbalances by changing the microbes in the skin and other body parts. Other factors such as aging, drugs, and disease may also alter the nature and amount of microbiome in the gut. Understanding the imbalances and how to address them paves the way for strategic interventions to address each causative factor. The studies attribute gut dysbiosis to neuroinflammation, suggesting that microbial imbalances may contribute to the development of some neurological diseases, especially when combined with other factors such as genetics and the environment [ 18 , 19 ]. The above findings prove that researchers can maintain the gut microbiota balance to promote neurological health, emphasizing the need for a proper diet, lifestyle habits, and strategic therapeutic interventions to balance the gut microbiome and prevent neuroinflammatory disorders.
The gut imbalances stem from dysregulations that affect gut permeability, encouraging inflammatory cytokines to get into the neurological system and trigger conditions such as Alzheimer’s and Parkinson’s diseases [ 20 , 21 , 22 ]. The current theme sets the pace for exploring gut-based therapies such as probiotics and prebiotics alongside other interventions to restore microbial balance. Other recent studies on animal models under controlled modulations of the gut microbiome revealed that introducing the gut bacteria lowered neuroinflammation, thereby improving mood and general behavior [ 23 , 24 , 25 ]. This evidence reveals the possibility of treating neurological issues through interventions that target the microbiome. Comprehensive clinical trials could help advance research on the subject and pave the way for practical solutions to gut-based health conditions.
4.3. Diseases Where the Gut Microbiota Could Be Pathogenic
The findings also revealed some diseases that could arise from gut microbiota imbalances. The cases where the gut microbiome emerged pathogenic include multiple sclerosis (MS), Parkinson’s disease, and Alzheimer’s disease. MS, characterized by CNS inflammation, has been linked to gut dysbiosis [ 26 ]. Gut microbiota contains many metabolites with immunomodulatory characteristics that may trigger pro- or anti-inflammatory responses as they interact with immune cells [ 27 ]. For instance, metabolites based on the Trp amino acid, such as indole and kynurenine, are pro-inflammatory, meaning they may trigger the onset of MS. At the same time, the gut microbiome may release anti-inflammatory short-chain fatty acids (SCFAs). The balance between these classes of metabolites determines the pathogenesis of MS in an individual [ 28 ].
The results also showed the possibility of Parkinson’s disease being pathogenic [ 29 ]. The reduced beneficial bacteria due to age and diet related to dysbiosis trigger Parkinson’s disease symptoms. Increased concentration of harmful bacteria also increases alpha-synuclein clumping, which forms Lewy body aggregations that may infiltrate the neurological system and affect some pathways [ 30 ]. Gut dysbiosis further raised intestinal permeability, known to increase neuroinflammation and oxidative stress, both of which directly contribute to Parkinson’s disease.
The gut microbiome also plays a pathogenic role in Alzheimer’s Disease progression. The studies show that bacteria in gut microbiota secret amyloids and lipopolysaccharides in large quantities, which modulate signaling pathways and accelerate the production of pro-inflammatory cytokines linked to the pathogenesis of Alzheimer’s Disease [ 31 ]. Variations in gut permeability could also destabilize the blood–brain barrier leading to metabolite imbalances and neuroinflammation. For instance, the release of SCFAs, which are anti-inflammatory in nature, could drop due to gut dysbiosis and increase the risk of Alzheimer’s disease [ 32 ].
4.4. Diseases Where Modulation of the Gut Microbiota Could Be Beneficial
The findings also showed that modulating the gut microbiota could alleviate certain disease symptoms. It emerged that among patients with autism spectrum disorder (ASD), depression, and anxiety, effective management of the gut microbiome could resolve the symptoms leading to quick recovery. For instance, healthcare practitioners can address ASD by improving the gastrointestinal and behavioral symptoms through techniques such as fecal transplantation, probiotics, breastfeeding and formulas, gluten- and casein-free (GFCF) diets, ketogenic therapy, and others [ 33 ]. Some compounds produced by gut bacteria are bioactive or neuroactive, and can impact brain function in Alzheimer’s patients. The research showed that people with the disease have a different gut microbiome compared to others. Relatively, dysregulating the immune system due to gut dysbiosis may trigger the body to form autoantibodies in ASD patients, which could reduce hypersensitive responses and improve one’s behavioral symptoms [ 34 ].
The gut microbiome resolves depressive symptoms by producing neurotransmitters such as serotonin, which regulate an individual’s mood after crossing the gut–brain axis [ 35 , 36 ]. It reduces inflammation levels in the signaling pathways in the vagus nerve to improve the person’s mental well-being. The gut bacteria also metabolizes tryptophan, an amino acid that promotes the secretion of serotonin [ 37 ]. This finding justifies the use of the gut microbiota to treat depression. The gut microbiota’s production of serotonin and other neurotransmitters further manages mood and stress response [ 38 ]. The hormones improve the ability of the vagus nerve to communicate and regulate mood. Balancing the gut microbiome promotes a healthy immune system, needed to minimize neuroinflammation and subsequent anxiety and stress. Other studies showed that some gut bacteria can secrete cortisol, one of the body’s key hormones for stress control.
Thus, whereas gut microbiome imbalance could influence pathogenesis of various diseases such as MS, Alzheimer’s, and Parkinson’s, it can also benefit conditions such as ASD, depression, and anxiety. Knowledge of the complex interactions between gut microbiota and neurological health is important to prevent the conditions and develop effective therapies to address their symptoms. Table 1 summarizes the relationships between the gut microbiota and human neurological health.
4.5. Mechanistic Pathways Involved in the Gut–Brain Axis
Multiple pathways, such as the vagus nerve and the immune system, link the brain to the gut and facilitate distinct communications. The systems facilitate gut–brain axis communication in either direction [ 39 , 40 , 41 , 42 , 43 ]. In fact, most studies showed that treatment and therapies on the vagus nerve can lower depression symptoms and other similar conditions [ 44 , 45 ]. The gut and CNS connect through metabolites released because of microbial bacteria, such as SCFAs [ 46 ]. Some of the SCFAs include propionate, butyrate, and acetate, and help to control neuroinflammation through the blood–brain barrier (BBB) [ 47 ]. The gut bacteria further produce indole-based derivatives, which regulate serotonin pathways that modulate a person’s mood and sleep [ 48 ]. The primary function of the immune system in this process is to act as a route of communication between the gut and the brain through cytokine and microglial activity. The pathways work together to create the gut–brain axis.
4.6. Emerging Evidence of the Brain Microbiome
Despite scientists discovering the link between the gut microbiome and the neurological system decades ago, the concept of a separate brain microbiome only emerged recently [ 49 , 50 , 51 , 52 ]. Advanced sequencing technologies on brain tissue revealed traces of microbial DNA, implying that some microbial colonies exist within the system. Some studies reveal that the microbes may enter the brain through the circulatory or lymphatic systems, potentially when the BBB is disrupted. The gap in the findings necessitates further research to confirm the mechanisms involved and the relative implications for cognitive health [ 53 , 54 ].
The data also showed that the brain microbiome acts similarly to the gut microbiome to influence neuron signaling, neuroinflammation, and synaptic plasticity [ 41 , 55 , 56 ]. For instance, cerebrospinal fluid has microbial byproducts that affect brain function [ 57 , 58 ]. The concept is, however, new and lacks sufficient research to justify its use. Further studies could help explore the subject in depth and offer insights and improvements.
4.7. Interplay Between the Gut and Brain Microbiomes
The gut–brain axis, where the gut and brain microbiomes interact, influences a person’s neurological health through multiple pathways [ 59 , 60 , 61 ]. For instance, the gut microbiome releases B cells, which move to the CNS and link to conditions such as multiple sclerosis [ 42 , 62 ]. Notably, SCFAs and other metabolites from the gut microbiome impact brain function, suggesting that they are secreted in the brain microbiome [ 63 ]. Advanced research shows that the gut–brain axis is a critical factor in autism [ 64 , 65 ]. Healthcare practitioners could adopt microbial interventions to reduce the its neurological symptoms and boost a person’s gastrointestinal health [ 66 , 67 ]. The results necessitate examining the gut and brain microbiome as a unified microbial system with the same function rather than two separate entities.
4.8. Challenges and Research Gaps
The positive progress in the research on gut–brain axis studies over the years has been marred with challenges and gaps, especially in healthcare settings. For instance, fecal microbiota transplantation (FMT) involves transferring fecal matter from one person to another, which is potentially unsafe. Another problem is that most studies rely on animal models, making their findings inapplicable to humans and could be misinterpreted.
A significant knowledge gap in the systematic review is the scanty research on the pathways and mechanisms involved in the gut–brain axis, especially communication between the gut microbiome and the brain. A few studies discuss the individual microbial species and metabolites that participate in the process, albeit unclearly. Further research, especially longitudinal studies, is necessary to explore and understand the pathways. Table 2 summarizes the most important findings.
4.9. Most Significant Findings
Table 2 summarizes the key findings from this systematic review.
5. Discussion
The gut microbiome significantly contributes to neurological health. The gut bacteria influence an individual’s mood, overall mental health, and even the pathogenesis of various disorders such as Parkinson’s disease. The links highlight the importance of the gut–brain axis and communication between the gut and the nervous system. The studies also attribute some conditions to imbalances in the gut microbiota. For instance, depression and anxiety are linked to gut dysbiosis, which may affect gut permeability and contribute to neuroinflammation. These effects are attributed to changes in gut microbial stability. For instance, changes in permeability cause bacterial amyloids, lipopolysaccharides, and cytokines to cross the blood–brain barrier into the neurological system and affect various pathways, thus causing symptoms related to Alzheimer’s, Parkinson’s, and other diseases.
Emerging evidence also suggests a strong relationship between nutrition, the gut microbiome, and brain function [ 68 , 69 , 70 , 71 ]. A healthy diet encourages the formation of a diverse gut microbiome whose bacteria produces valuable compounds such as SCFAs in large quantities. Thus, a healthy diet indirectly supports brain development and function, while a poor diet increases the risk of gut dysbiosis linked to neuroinflammation and conditions such as Alzheimer’s disease [ 72 ]. Scientists and physicians recognize the therapeutic opportunity the gut–brain axis offers to explore practical interventions and practices, especially for diseases such as Alzheimer’s and Parkinson’s [ 69 , 73 , 74 , 75 ].
The connection through systems such as the vagus nerve means these pathways can be targeted in such interventions. Some clinical trials have shown that adding new strains to a patient’s gut microbiome could strengthen it and improve their cognition [ 68 , 76 ]. These bacteria include bifidobacterium, lactobacillus, and others [ 77 , 78 , 79 , 80 ]. This information can be used to develop effective treatments such as FMT for brain-related disorders [ 40 , 81 , 82 ]. However, safety concerns limit its applicability, necessitating standard FMT protocols and additional research on how microbiota transfer.
5.1. Study Limitations
Certain limitations influenced the study outcomes and could affect the strength and quality of the findings. The limitations border reliance on correlation data, variability of study designs, non-standardized microbiome analysis technique, minimal understanding of the mechanistic pathways, little clinical evidence on microbiome-based therapies, and the emerging but inconclusive research on the brain microbiome. Most reviewed studies relied on correlational data to understand the relationship between gut microbiota and neurological health, avoiding the causal relationship. The minimal longitudinal studies limit the knowledge of whether the imbalances in the gut microbiota directly contribute to the consequences or emerge as a result of the conditions. The research also varied the study designs, limiting the generalization of the findings across diverse disease and demographic conditions. The non-standardized microbiome analysis technique limited the ability to compare findings across distinct research due to varying sample collection methods, data interpretation, and depth sequencing. Little knowledge of the mechanistic pathways limits information on how specific microbial species and metabolic pathways influence brain function, limiting the outcome. The limited clinical evidence on microbiome-based therapies undermines the knowledge of their efficiency and requires more research to reveal their efficacy. Finally, the emerging and inconclusive research on brain microbiomes is inconclusive, inconsistent, and controversial. Advanced research would offer insights into the matter.
5.2. Study Implications
The study findings significantly imply practice in neuroscience, mental health, and clinical practice. The revelation of how gut microbiota influences neurological function increases the evidence on the subject and could contribute to future studies. Thus, the key implications include the following: Advancements in Neurological and Psychiatric Research —This research reveals how gut microbiota influences neuroinflammation, neurotransmitter regulation, and cognitive function and presents new perspective to handle neurological diseases such as Alzheimer’s, Parkinson’s, and multiple sclerosis Potential for Microbiome-Based Therapies —The results reveal the importance of probiotics, prebiotics, and fecal microbiota transplantation to address the neurodegenerative and psychiatric disorders Public Health and Preventive Strategies —The relationship between gut microbiota and neurological health reveals the need for a proper diet, lifestyle, and environmental factors to prevent neurological diseases. Public health policies could improve the preventive measures to address the issues. Clinical and Diagnostics Innovations —The gut bacteria composition could be a biomarker for detecting early neurodegenerative and psychiatric disorders, permitting earlier interventions and proper disease management. Interdisciplinary Collaboration —The findings reveal the need for neuroscientists, microbiologists, and clinicians to collaborate and establish a comprehensive knowledge of the gut–brain axis and propose strategic interventions.
5.3. Study Recommendations
The findings of this study point to a few recommendations that could improve research, clinical practice, and public health strategies to mitigate issues with the gut–brain axis and neurological health. The following recommendations could apply to the current study: Future research directions —The findings provide direction for future longitudinal and causal studies, mechanistic investigations, and brain microbiome validation. Clinical and Therapeutic Applications —The findings could help establish the development of microbiome-based therapies, personalized medicine approaches, and early diagnosis and biomarker identification. Public Health and Lifestyle Recommendations —Healthcare stakeholders should adopt effective stress and lifestyle management, microbiome-friendly diets, and education and awareness campaigns. Interdisciplinary Collaboration —Interdisciplinary teams could collaborate to integrate neuroscience and microbiome research and policy development for gut health interventions.
6. Conclusions
This systematic review reveals the role of gut microbiota in neurological health. It influences neurodegenerative diseases, cognitive functions, mental health disorders, autoimmune diseases, and cancer risks. The results reveal a strong gut–brain connection in which microbial imbalances cause neuroinflammation, neurotransmitter dysregulation, and disease progression. The studies demonstrate that altering gut microbiota triggers conditions such as Alzheimer’s, Parkinson’s, depression, and schizophrenia, revealing the need for microbiome health. Significant progress has been made on the gut–brain axis; however, major gaps exist in the causal relationships, the microbial mechanisms, and the standardized microbiome diagnostic tools. Researchers could conduct further trials to validate the long-term effectiveness of the interventions. The study implications border clinical practice, public health strategies, and therapeutic advancements. Subsequent research should focus on longitudinal research, standardized microbiome practice, and interdisciplinary collaborations. The recommended strategies would streamline the treatment of neurological and psychiatric health issues to improve population health.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Data Availability Statement
The data presented in this study are available on request from the corresponding author due to privacy reasons.
Conflicts of Interest
The authors declare no conflict of interest.
References
1. Loh J. Mak W. Tan L. Ng C. Chan H. Yeow S. Foo J. Ong Y. How C. Khaw K. Microbiota-gut-brain axis and its therapeutic applications in neurodegenerative diseases Sign. Trans. Tar. Ther. 2024 9 37 10.1038/s41392-024-01743-1 PMC10869798 38360862
2. Foster J. Rinaman L. Cryan J. Stress & the gut-brain axis: Regulation by the microbiome Neurobiol. Stress 2017 7 124 136 10.1016/j.ynstr.2017.03.001 29276734 PMC5736941
3. Morais L. Schreiber H. Mazmanian S. The gut microbiota-brain axis in behavior and brain disorders Nat. Rev. Microbiol. 2021 19 241 255 10.1038/s41579-020-00460-0 33093662
4. Fried S. Wemelle E. Cani P. Knauf C. Interactions between the microbiota and enteric nervous system during gut-brain disorders Neuropharmacology 2021 197 108721 10.1016/j.neuropharm.2021.108721 34274348
5. Toader C. Dobrin N. Costea D. Glavan L. Busuioc R. Dumitrascu D. Bratu B. Costin H. Ciurea A. Mind, mood, and microbiota—Gut-brain axis in psychiatric disorders Int. J. Mol. Sci. 2024 25 3340 10.3390/ijms25063340 38542314 PMC10970241
6. Rutsch A. Kantsjo J. Ronchi F. The gut-brain axis: How microbiota and host inflammasome influence brain physiology and pathology Front. Psychol. 2020 11 604179 10.3389/fimmu.2020.604179 PMC7758428 33362788
7. Socala K. Doboszewska U. Szopa A. Serefko A. Wlodarczyk M. Zielinska A. Poleszak E. Fichna J. Wlaz P. The role of microbiota-gut-brain axis in neuropsychiatric and neurological disorders Pharmacol. Res. 2021 172 105840 10.1016/j.phrs.2021.105840 34450312
8. Barrio C. Arias-Sánchez S. Martín-Monzón I. The gut microbiota-brain axis, psychobiotics and its influence on brain and behavior: A systematic review Psychoneuroendocrinology 2022 137 105640 10.1016/j.psyneuen.2021.105640 34942539
9. Simpson C.A. Diaz-Arteche C. Eliby D. Schwartz O.S. Simmons J.G. Cowan C.S.M. The gut microbiota in anxiety and depression—A systematic review Clin. Psychol. Rev. 2021 83 101943 10.1016/j.cpr.2020.101943 33271426
10. Xu Q. Ni J.J. Han B.X. Yan S.S. Wei X.T. Feng G.J. Zhang H. Zhang L. Li B. Pei Y.F. Causal relationship between gut microbiota and autoimmune diseases: A two-sample Mendelian randomization study Front. Immunol. 2022 12 746998 10.3389/fimmu.2021.746998 35140703 PMC8819003
11. Wang Y. Li N. Yang J.J. Zhao D.M. Chen B. Zhang G.Q. Chen S. Cao R.F. Yu H. Zhao C.Y. Probiotics and fructo-oligosaccharide intervention modulate the microbiota-gut brain axis to improve autism spectrum reducing also the hyper-serotonergic state and the dopamine metabolism disorder Pharmacol. Res. 2020 157 104784 10.1016/j.phrs.2020.104784 32305492
12. Kim C.S. Cha L. Sim M. Jung S. Chun W.Y. Baik H.W. Shin D.M. Probiotic supplementation improves cognitive function and mood with changes in gut microbiota in community-dwelling older adults: A randomized, double-blind, placebo-controlled, multicenter trial J. Gerontol. A Biol. Sci. Med. Sci. 2021 76 32 40 10.1093/gerona/glaa090 32300799 PMC7861012
13. Alli S.R. Gorbovskaya I. Liu J.C.W. Kolla N.J. Brown L. Müller D.J. The gut microbiome in depression and potential benefit of prebiotics, probiotics, and synbiotics: A systematic review of clinical trials and observational studies Int. J. Mol. Sci. 2022 23 4494 10.3390/ijms23094494 35562885 PMC9101152
14. McGuinness A.J. Davis J.A. Dawson S.L. Loughman A. Collier F. O’Hely M. Simpson C.A. Green J. Marx W. Hair C. A systematic review of gut microbiota composition in observational studies of major depressive disorder, bipolar disorder, and schizophrenia Mol. Psychiatry 2022 27 1920 1935 10.1038/s41380-022-01456-3 35194166 PMC9126816
15. Kelly J.R. Clarke G. Cryan J.F. Dinan T.G. Brain-gut-microbiota axis: Challenges for translation in psychiatry Ann. Epidemiol. 2016 26 366 372 10.1016/j.annepidem.2016.02.008 27005587
16. Eastwood J. Walton G. Van Hemert S. Williams C. Lamport D. The effect of probiotics on cognitive function across the human lifespan: A systematic review Neurosci. Biobehav. Rev. 2021 128 311 327 10.1016/j.neubiorev.2021.06.032 34171323
17. Korteniemi J. Karlsson L. Aatsinki A. Systematic review: Autism spectrum disorder and the gut microbiota Acta Psychiatr. Scand. 2023 148 242 254 10.1111/acps.13587 37395517
18. Cheng Y. Tan G. Zhu Q. Wang C. Ruan G. Ying S. Qie J. Hu X. Xiao Z. Xu F. Efficacy of fecal microbiota transplantation in patients with Parkinson’s disease: Clinical trial results from a randomized, placebo-controlled design Gut Microbes 2023 15 2284247 10.1080/19490976.2023.2284247 38057970 PMC10841011
19. Fei Y. Wang R. Lu J. Peng S. Yang S. Wang Y. Zheng K. Li R. Lin L. Li M. Probiotic intervention benefits multiple neural behaviors in older adults with mild cognitive impairment Geriatr. Nurs. 2023 51 167 175 10.1016/j.gerinurse.2023.03.006 36990042
20. Batista K.S. Cintra V.M. Lucena P.A.F. Manhães-de-Castro R. Toscano A.E. Costa L.P. Queiroz M.E.B.S. de Andrade S.M. Guzman-Quevedo O. Aquino J.S. The role of vitamin B12 in viral infections: A comprehensive review of its relationship with the muscle-gut-brain axis and implications for SARS-CoV-2 infection Nutr. Rev. 2022 80 561 578 10.1093/nutrit/nuab092 34791425 PMC8689946
21. Pröbstel A.K. Zhou X. Baumann R. Wischnewski S. Kutza M. Rojas O.L. Sellrie K. Bischof A. Kim K. Ramesh A. Gut microbiota-specific IgA(+) B cells traffic to the CNS in active multiple sclerosis Sci. Immunol. 2020 5 eabc7191 10.1126/sciimmunol.abc7191 33219152 PMC8043673
22. Handajani Y.S. Hengky A. Schröder-Butterfill E. Hogervorst E. Turana Y. Probiotic supplementation improved cognitive function in cognitively impaired and healthy older adults: A systematic review of recent trials Neurol. Sci. 2023 44 1163 1169 10.1007/s10072-022-06540-8 36529793
23. Zhou X. Wu X. Wu Y. Yang L. Shi E. Ding W. Chen L. Shi X. Feng X. Su C. Indole-3-propionic acid, a gut microbiota metabolite, protects against the development of postoperative delirium Ann. Surg. 2023 278 e1164 e1174 10.1097/SLA.0000000000005886 37185230 PMC10603211
24. Heravi F.S. Naseri K. Hu H. Gut microbiota composition in patients with neurodegenerative disorders (Parkinson’s and Alzheimer’s) and healthy controls: A systematic review Nutrients 2023 15 4365 10.3390/nu15204365 37892440 PMC10609969
25. Önning G. Montelius C. Hillman M. Larsson N. Intake of Lactiplantibacillus plantarum HEAL9 improves cognition in moderately stressed subjects: A randomized controlled study Nutrients 2023 15 3466 10.3390/nu15153466 37571403 PMC10421450
26. Noto D. Miyake S. Gut dysbiosis and multiple sclerosis Clin. Immunol. 2022 235 108380 10.1016/j.clim.2020.108380 32169440
27. Correale J. Hohfeld R. Baranzini S. The role of the gut microbiota in multiple sclerosis Nat. Rev. Neurol. 2022 18 544 558 10.1038/s41582-022-00697-8 35931825
28. Altieri C. Speranza B. Corbo M. Sinigaglia M. Bevilacqua A. Gut microbiota, and multiple sclerosis: Background, evidence, and perspectives Nutrients 2023 15 942 10.3390/nu15040942 36839299 PMC9965298
29. Zhu M. Liu X. Ye Y. Yan X. Cheng Y. Zhao L. Chen F. Ling Z. Gut microbiota: A novel therapeutic target for Parkinson’s disease Front. Immunol. 2022 13 937555 10.3389/fimmu.2022.937555 35812394 PMC9263276
30. Romano S. Savva G. Bedarf J. Charles I. Hildebrand F. Narbad A. Meta-analysis of the Parkinson’s disease gut microbiome suggests alterations linked to intestinal inflammation NPJ Park. Dis. 2021 7 27 10.1038/s41531-021-00156-z PMC7946946 33692356
31. Jiang C. Li G. Huang P. Liu Z. Zhao B. The gut microbiota and Alzheimer’s disease J. Alzh. Dis. 2017 58 1 15 10.3233/JAD-161141 28372330
32. Seo D. Holtzman D. Current understanding of the Alzheimer’s disease-associated microbiome and therapeutic strategies Exp. Mol. Med. 2024 56 86 94 10.1038/s12276-023-01146-2 38172602 PMC10834451
33. Mehra A. Arora G. Sahni G. Kaur M. Singh H. Sing B. Kaur S. Gut microbiota and autism spectrum disorder: From pathogenesis to potential therapeutic perspectives J. Tradit. Complement. Med. 2023 13 135 149 10.1016/j.jtcme.2022.03.001 36970459 PMC10037072
34. Kumar A. Pramanik J. Goyal N. Chauhan D. Sivamaruthi B. Prajapati B. Chaiyasut C. Gut microbiota in anxiety and depression: Unveiling the relationships and management options Pharmaceuticals 2023 16 565 10.3390/ph16040565 37111321 PMC10146621
35. Liu L. Wang H. Chen X. Zhang Y. Zhang H. Xie P. Gut microbiota and its metabolites in depression: From pathogenesis to treatment eBioMedicine 2023 90 104257 10.1016/j.ebiom.2023.104527 36963238 PMC10051028
36. Limbana T. Khan F. Eskander N. Gut microbiome and depression: How microbes affect the way we think Cureus 2020 12 e9966 10.7759/cureus.9966 32983670 PMC7510518
37. Butler M. Bastiaanssen T. Long-Smith C. Morkl S. Berding K. Ritz N. Strain C. Patangia D. Patel S. Stanton C. The gut microbiome in social disorder: Evidence of altered composition and function Transl. Psych. 2023 13 95 10.1038/s41398-023-02325-5 36941248 PMC10027687
38. Dong Z. Xie Q. Yuan Y. Shen X. Hao Y. Li J. Xu H. Kuang W. Strain-level structure of gut microbiome showed potential association with cognitive function in major depressive disorder: A pilot study J. Affect. Disord. 2023 341 236 247 10.1016/j.jad.2023.08.129 37657622
39. Nazarova L. Liu H. Xie H. Wang L. Ding H. An H. Huang D. Targeting gut-brain axis through scalp-abdominal electroacupuncture in Parkinson’s disease Brain Res. 2022 1790 147956 10.1016/j.brainres.2022.147956 35660372
40. Wu J. Masuy I. Biesiekierski J.R. Fitzke H.E. Parikh C. Schofield L. Shaikh H. Bhagwanani A. Aziz Q. Taylor S.A. Gut-brain axis dysfunction underlies FODMAP-induced symptom generation in irritable bowel syndrome Aliment. Pharmacol. Ther. 2022 55 670 682 10.1111/apt.16812 35166384
41. Komorniak N. Kaczmarczyk M. Łoniewski I. Martynova-Van Kley A. Nalian A. Wroński M. Kaseja K. Kowalewski B. Folwarski M. Stachowska E. Analysis of the efficacy of diet and short-term probiotic intervention on depressive symptoms in patients after bariatric surgery: A randomized double-blind placebo-controlled pilot Nutrients 2023 15 4905 10.3390/nu15234905 38068763 PMC10707788
42. Olavarría-Ramírez L. Cooney-Quane J. Murphy G. McCafferty C.P. Cryan J.F. Dockray S. A systematic review of the effects of gut microbiota depletion on social and anxiety-related behaviours in adult rodents: Implications for translational research Neurosci. Biobehav. Rev. 2023 145 105013 10.1016/j.neubiorev.2022.105013 36566805
43. Xiong R. Li J. Cheng J. Zhou D. Wu S. Huang S. Saimaiti A. Yang Z. Gan R. Li H. The role of the gut microbiota in anxiety, depression, and other mental disorders as well as the protective effects of dietary components Nutrients 2023 15 3258 10.3390/nu15143258 37513676 PMC10384867
44. Anton-Păduraru D.T. Trofin F. Nastase E.V. Miftode R.S. Miftode I.L. Trandafirescu M.F. Cojocaru E. Țarcă E. Mindru D.E. Dorneanu O.S. The role of the gut microbiota in anorexia nervosa in children and adults—Systematic review Int. J. Mol. Sci. 2023 25 41 10.3390/ijms25010041 38203211 PMC10779038
45. Arneth B.M. Gut-brain axis biochemical signaling from the gastrointestinal tract to the central nervous system: Gut dysbiosis and altered brain function Postgrad. Med. J. 2018 94 446 452 10.1136/postgradmedj-2017-135424 30026389
46. Hassib L. de Oliveira C.L. Rouvier G.A. Kanashiro A. Guimarães F.S. Ferreira F.R. Maternal microbiome disturbance induces deficits in the offspring’s behaviors: A systematic review and meta-analysis Gut Microbes. 2023 15 2226282 10.1080/19490976.2023.2226282 37400971 PMC10321199
47. Ticinesi A. Tana C. Nouvenne A. Prati B. Lauretani F. Meschi T. Gut microbiota, cognitive frailty and dementia in older individuals: A systematic review Clin. Interv. Aging 2018 13 1497 1511 10.2147/CIA.S139163 30214170 PMC6120508
48. Li J. Zhao J. Ze X. Li L. Li Y. Zhou Z. Wu S. Jia W. Liu M. Li Y. Lacticaseibacillus paracasei 207-27 alters the microbiota-gut-brain axis to improve wearable device-measured sleep duration in healthy adults: A randomized, double-blind, placebo-controlled trial Food Funct. 2024 15 10732 10745 10.1039/D4FO01684J 39385735
49. Frileux S. Boltri M. Doré J. Leboyer M. Roux P. Cognition and gut microbiota in schizophrenia spectrum and mood disorders: A systematic review Neurosci. Biobehav. Rev. 2024 162 105722 10.1016/j.neubiorev.2024.105722 38754717
50. Zhang Z. Li D. Xie F. Zhang H. The causal relationship between gut microbiota and neuroblastoma: A bidirectional Mendelian randomization analysis and meta-analysis Microbiol. Spectr. 2024 12 e0365623 10.1128/spectrum.03656-23 38411074 PMC10986465
51. Wang Z. Wu M. Pan Y. Wang Q. Zhang L. Tang F. Lu B. Zhong S. Causal relationships between gut microbiota and hypothyroidism: A Mendelian randomization study Endocrine 2024 83 708 718 10.1007/s12020-023-03538-w 37736821
52. Khine W.W.T. Voong M.L. Ng T.K.S. Feng L. Rane G.A. Kumar A.P. Kua E.H. Mahendran R. Mahendran R. Lee Y.K. Mental awareness improved mild cognitive impairment and modulated gut microbiome Aging 2020 12 24371 24393 10.18632/aging.202277 33318317 PMC7762482
53. Chen L.L. Abbaspour A. Mkoma G.F. Bulik C.M. Rück C. Djurfeldt D. Gut microbiota in psychiatric disorders: A systematic review Psychosom. Med. 2021 83 679 692 10.1097/PSY.0000000000000959 34117156 PMC8428865
54. Naomi R. Embong H. Othman F. Ghazi H.F. Maruthey N. Bahari H. Probiotics for Alzheimer’s disease: A systematic review Nutrients 2021 14 20 10.3390/nu14010020 35010895 PMC8746506
55. Bundgaard-Nielsen C. Knudsen J. Leutscher P.D.C. Lauritsen M.B. Nyegaard M. Hagstrøm S. Sørensen S. Gut microbiota profiles of autism spectrum disorder and attention-deficit/hyperactivity disorder: A systematic literature review Gut Microbes. 2020 11 1172 1187 10.1080/19490976.2020.1748258 32329656 PMC7524304
56. Yang J. Fu X. Liao X. Li Y. Effects of gut microbial-based treatments on gut microbiota, behavioral symptoms, and gastrointestinal symptoms in children with autism spectrum disorder: A systematic review Psychiatry Res. 2020 293 113471 10.1016/j.psychres.2020.113471 33198044
57. Wang H. Braun C. Enck P. Effects of rifaximin on central responses to social stress—A pilot experiment Neurotherapeutics 2018 15 807 818 10.1007/s13311-018-0627-2 29713909 PMC6095772
58. Kossowska M. Olejniczak S. Karbowiak M. Mosiej W. Zielińska D. Brzezicka A. The interplay between gut microbiota and cognitive functioning in the healthy aging population: A systematic review Nutrients 2024 16 852 10.3390/nu16060852 38542764 PMC10974508
59. Arulsamy A. Tan Q.Y. Balasubramaniam V. O’Brien T.J. Shaikh M.F. Gut microbiota and epilepsy: A systematic review on their relationship and possible therapeutics ACS Chem. Neurosci. 2020 11 3488 3498 10.1021/acschemneuro.0c00431 33064448
60. Di Lodovico L. Mondot S. Doré J. Mack I. Hanachi M. Gorwood P. Anorexia nervosa and gut microbiota: A systematic review and quantitative synthesis of pooled microbiological data Prog. Neuropsychopharmacol. Biol. Psychiatry 2021 106 110114 10.1016/j.pnpbp.2020.110114 32971217
61. Baske M.M. Timmerman K.C. Garmo L.G. Freitas M.N. McCollum K.A. Ren T.Y. Fecal microbiota transplant on Escherichia-Shigella gut composition and its potential role in the treatment of generalized anxiety disorder: A systematic review J. Affect Disord. 2024 354 309 317 10.1016/j.jad.2024.03.088 38499070
62. Van Nieuwenhove T. Rasschaert G. Kharagjitsingh A. Keymeulen B. Reynaert H. Kindt S. The prevalence of disorders of the gut-brain axis in type 2 diabetes mellitus patients with metabolic dysfunction-associated fatty liver disease: An observational study Acta Gastroenterol. Belg. 2021 84 541 547 10.51821/84.4.003 34965034
63. Zhang Z. Cheng N. Liang J. Deng Y. Xiang P. Hei Z. Li X. Gut microbiota changes in animal models of spinal cord injury: A preclinical systematic review and meta-analysis Ann. Med. 2023 55 2269379 10.1080/07853890.2023.2269379 37851840 PMC10586076
64. Beltrán-Velasco A.I. Reiriz M. Uceda S. Echeverry-Alzate V. Lactiplantibacillus (Lactobacillus) plantarum as a complementary treatment to improve symptomatology in neurodegenerative disease: A systematic review of open access literature Int. J. Mol. Sci. 2024 25 3010 10.3390/ijms25053010 38474254 PMC10931784
65. Wong L.C. Hsu C.J. Wu Y.T. Chu H.F. Lin J.H. Wang H.P. Hu S.C. Tsai Y.C. Tsai W.C. Lee W.T. Investigating the impact of probiotic on neurological outcomes in Rett syndrome: A randomized, double-blind, and placebo-controlled pilot study Autism 2024 28 2267 2281 10.1177/13623613231225899 38361371
66. Diebold M. Meola M. Purushothaman S. Siewert L.K. Pössnecker E. Roloff T. Lindberg R.L. Kuhle J. Kappos L. Derfuss T. Gut microbiota composition as a candidate risk factor for dimethyl fumarate-induced lymphopenia in multiple sclerosis Gut Microbes. 2022 14 2147055 10.1080/19490976.2022.2147055 36398902 PMC9677991
67. Li S. Hua D. Wang Q. Yang L. Wang X. Luo A. Yang C. The role of bacteria and its derived metabolites in chronic pain and depression: Recent findings and research progress Int. J. Neuropsychopharmacol. 2020 23 26 41 10.1093/ijnp/pyz061 31760425 PMC7064053
68. Zhang D. Lan Y. Zhang J. Cao M. Yang X. Wang X. Effects of early-life gut microbiota on the neurodevelopmental outcomes of preterm infants: A multi-center, longitudinal observational study in China Eur. J. Pediatr. 2024 183 1733 1740 10.1007/s00431-024-05423-8 38231236
69. Herselman M.F. Bailey S. Deo P. Zhou X.F. Gunn K.M. Bobrovskaya L. The effects of walnuts and academic stress on mental health, general well-being, and the gut microbiota in a sample of university students: A randomized clinical trial Nutrients 2022 14 4776 10.3390/nu14224776 36432461 PMC9697272
70. Petakh P. Oksenych V. Kamyshna I. Boisak I. Lyubomirskaya K. Kamyshnyi O. Exploring the interplay between posttraumatic stress disorder, gut microbiota, and inflammatory biomarkers: A comprehensive meta-analysis Front. Immunol. 2024 15 1349883 10.3389/fimmu.2024.1349883 38410510 PMC10895958
71. Karakula-Juchnowicz H. Rog J. Juchnowicz D. Łoniewski I. Skonieczna-Żydecka K. Krukow P. Futyma-Jedrzejewska M. Kaczmarczyk M. The study evaluating the effect of probiotic supplementation on the mental status, inflammation, and intestinal barrier in major depressive disorder patients using gluten-free or gluten-containing diet (SANGUT study): A 12-week, randomized, double-blind, and placebo-controlled clinical study protocol Nutr. J. 2019 18 50 10.1186/s12937-019-0475-x 31472678 PMC6717641
72. Li W. Zhou X. Yuan S. Wang L. Yu L. Sun J. Chen J. Xiao Q. Wan Z. Zheng J.S. Exploring the complex relationship between gut microbiota and risk of colorectal neoplasia using bidirectional mendelian randomization analysis Cancer Epidemiol. Biomark. Prev. 2023 32 809 817 10.1158/1055-9965.EPI-22-0724 37012201 PMC10233354
73. Davies C. Mishra D. Eshraghi R.S. Mittal J. Sinha R. Bulut E. Mittal R. Eshraghi A.A. Altering the gut microbiome to potentially modulate behavioral manifestations in autism spectrum disorders: A systematic review Neurosci. Biobehav. Rev. 2021 128 549 557 10.1016/j.neubiorev.2021.07.001 34271306
74. Zhu Y. Zhu J. Song G. The impact of aerobic exercise training on cognitive function and gut microbiota in methamphetamine-dependent individuals in the community Physiol. Behav. 2023 270 114302 10.1016/j.physbeh.2023.114302 37474085
75. Luo Y. Li Z. Gu L. Zhang K. Fermented dairy foods consumption and depressive symptoms: A meta-analysis of cohort studies PLoS ONE 2023 18 e0281346 10.1371/journal.pone.0281346 36745637 PMC9901789
76. Zhu B. Shen J. Jiang R. Jin L. Zhan G. Liu J. Sha Q. Xu R. Miao L. Yang C. Abnormalities in gut microbiota and serum metabolites in hemodialysis patients with mild cognitive decline: A single-center observational study Psychopharmacology 2020 237 2739 2752 10.1007/s00213-020-05569-x 32601991
77. Ceccarelli G. Fratino M. Selvaggi C. Giustini N. Serafino S. Schietroma I. Corano Scheri G. Pavone P. Passavanti G. Alunni Fegatelli D. A pilot study on the effects of probiotic supplementation on neuropsychological performance and microRNA-29a-c levels in antiretroviral-treated HIV-1-infected patients Brain Behav. 2017 7 e00756 10.1002/brb3.756 28828217 PMC5561317
78. Yang C. Xiao H. Zhu H. Du Y. Wang L. Revealing the gut microbiome mystery: A meta-analysis revealing differences between individuals with autism spectrum disorder and neurotypical children Biosci. Trends 2024 18 233 249 10.5582/bst.2024.01123 38897955
79. Bonnechère B. Amin N. van Duijn C. What are the key gut microbiota involved in neurological diseases? A systematic review Int. J. Mol. Sci. 2022 23 13665 10.3390/ijms232213665 36430144 PMC9696257
80. Althubeati S. Avery A. Tench C.R. Lobo D.N. Salter A. Eldeghaidy S. Mapping brain activity of gut-brain signaling to appetite and satiety in healthy adults: A systematic review and functional neuroimaging meta-analysis Neurosci. Biobehav. Rev. 2022 136 104603 10.1016/j.neubiorev.2022.104603 35276299 PMC9096878
81. Saleh-Ghadimi S. Dehghan P. Sarmadi B. Maleki P. Improvement of sleep by resistant dextrin prebiotic in type 2 diabetic women coincides with attenuation of metabolic endotoxemia: Involvement of gut-brain axis J. Sci. Food Agric. 2022 102 5229 5237 10.1002/jsfa.11876 35306660
82. Nikrad N. Farhangi M.A. Fard Tabrizi F.P. Vaezi M. Mahmoudpour A. Mesgari-Abbasi M. The effect of calorie-restriction along with thylakoid membranes of spinach on the gut-brain Axis Pathway and oxidative stress biomarkers in obese women with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled clinical trial J. Ovarian Res. 2023 16 216 10.1186/s13048-023-01288-x 37968684 PMC10652637